Workflow
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
Instil BioInstil Bio(US:TIL) Globenewswireยท2025-05-13 11:00

Initiation of U.S. clinical study of AXN-2510/IMM2510 in combination with chemotherapy in 1L NSCLC anticipated before the end of 2025, assuming receipt of necessary regulatory approvals DALLAS, May 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its first quarter 2025 financial results and provided a corporate update. Recent Highlights: First Quarter 2025 Financial and Opera ...